Earnings Call Intelligence Subscribe
Home › Call Sheets › VRTX › Q4'25
Call sheet · Q4'25

Vertex Pharmaceuticals (VRTX)

Q4'25 earnings call · held February 12, 2026 · compared with the Q3'25 call · management-credibility review
11/12
Disclosure score
2 medium, 4 low flags
Financial quality
Bottom line
The sleeper story is **renal becoming the fourth major franchise** - POBI isn't just one drug but a platform across IgAN, membranous, and myasthenia with Duncan explicitly saying it will 'rival the scale of CF.' The obvious headline is solid execution across all launches, but the real constraint is **OpEx inflation outpacing revenue growth** with 13-15% expense increases vs 8-9% revenue guidance. Reshma's most revealing quote: 'If it is possible to do better for CF patients, we are committed to doing so' - the relentless innovation mindset that built this company but now risks margin compression. **My view changes if POBI interim data disappoints** - the entire renal investment thesis hinges on that single readout in late 2026.

The 30-second version

  • SLEEPER STORY: Renal franchise is quietly becoming the next CF-sized opportunity
  • CF margins are the real story behind the revenue beat
  • Gernavix gross-to-net is masking real adoption momentum

What changed this quarter

MetricQ3'25Q4'25Change
Total Revenue$2.8B (+8% YoY Q3)$3.2B (+10% YoY Q4)+14% QoQ acceleration from prior quarter
CF Revenue Growth7% YoY (Q3)7% YoY (full year)Consistent mid-single digit growth maintained
KASJEVY Revenue$17M (Q3)$54M (Q4)+218% QoQ massive acceleration
KASJEVY Patient Infusions10 patients (Q3)30 patients (Q4)+200% QoQ infusion ramp
Gernavix Revenue$20M (Q3)$27M (Q4)+35% QoQ despite PSP headwinds
Gross MarginNot disclosed Q385.7% (Q4)Charlie called this '2026 proxy level'
Non-GAAP EPS$4.80 (Q3)$5.30 (Q4)+26% YoY earnings acceleration
Operating Expenses$1.28B (Q3)$1.4B (Q4)+9% QoQ driven by renal buildout
Cash Position$12B (Q3)$12.3B (Q4)Stable despite $2B share buybacks
2026 Revenue GuidanceNot provided$12.95-13.1B8-9% growth guided, $500M+ non-CF

Accountability tracked

8 new promises made4 narrative shifts flagged6 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full VRTX Q4'25 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.